Bristol-Myers
Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared
laboratory space designed as a launchpad for life-sciences and biotech
startups, today announced that Neutrolis and Remora Therapeutics are the
winners of Bristol-Myers Squibb’s 2017 Golden Tickets for LabCentral. As
a platinum sponsor of LabCentral, Bristol-Myers Squibb can select up to
two innovative life-sciences and biotech startup companies per year of
active sponsorship for “Golden Tickets,” which underwrite the cost of
one lab bench for one year in LabCentral’s Kendall Square facility.
“We are delighted to award Golden Tickets to Neutrolis and Remora
Therapeutics, two emerging, innovative companies with significant
scientific potential,” said Carl Decicco, Ph.D., Head of Discovery at
Bristol-Myers Squibb. “The winners align with our commitment to enabling
scientific innovation in our research areas of focus. We look forward to
seeing these promising companies advance their research programs at
LabCentral. Our sponsorship of LabCentral has facilitated important
collaborations between Bristol-Myers Squibb researchers and the
Cambridge community, as we prepare for our research site opening in
Cambridge next year.”
Neutrolis is a preclinical drug discovery company focused on researching
new potential treatment options for inflammatory diseases where
uncontrolled neutrophilic inflammation may be implicated, such as lupus
and sepsis. Neutrophils are the predominant white blood cells present
during acute inflammation. When patients are unable to regulate this
inflammatory process, it can lead to worsening of disease. Using its
proprietary genetic technology platform, Neutrolis is developing
therapeutics with the goal of neutralizing excessive neutrophilic
inflammation, as well as companion diagnostics to identify patients who
are most likely to benefit from such therapeutics.
Remora Therapeutics is a preclinical-stage biotechnology company focused
on developing novel platelet-based cell therapies. Platelets are best
known for their role in blood clotting, but they are also involved in
the pathogenesis of many major human diseases, including cancer and
conditions of autoimmunity. Remora’s proprietary technology is designed
to engineer platelets to fight disease, and improve the quality of life
for patients living with debilitating illness.
“Bristol-Myers Squibb’s first two Golden Ticket winners, PanTher and
Suono Bio, have each met important research milestones and have been
terrific contributors to the LabCentral community,” commented LabCentral
Cofounder and President Johannes Fruehauf, M.D., Ph.D. “We are pleased
to welcome Neutrolis and Remora Therapeutics – impressive startups – and
we expect that they will likewise thrive here.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter,
YouTube
and Facebook.
About LabCentral (
www.labcentral.org
;
twitter @labcentral)
LabCentral is a first-of-its-kind shared laboratory workspace in the
heart of the Kendall Square, Cambridge, biotech innovation hub. Designed
as a launchpad for high-potential life-sciences and biotech startups, it
offers everything startups need to begin laboratory operations on day
one and move their science forward faster and more cost-efficiently.
This includes: fully permitted laboratory and office space, first-class
facility and administrative support, skilled laboratory personnel, a
domain-relevant expert speaker series ‒ as well as the other critical
services and support. A private, nonprofit institution, LabCentral’s
first site opened in 2013, thanks to a capital grant from the
Massachusetts Life Sciences Center, with support from its real-estate
partner, MIT. Founding sponsors include Triumvirate Environmental and
Johnson & Johnson Innovation. To accommodate demand for its growing
startups, LabCentral, with support from Pfizer, Inc., plans to open LabCentral
610 in December 2017. In 2018, LabCentral will have capacity to
serve a total of ~450 scientists and entrepreneurs in about 70 companies
across its two-building campus.
Bristol-Myers Squibb Media:Chrissy Trank, 609-252-5609 christina.trank@bms.com orInvestors:Bill Szablewski, 609-252-5894 william.szablewski@bms.com or LabCentral Caroline Grossman, 781-771-5579 cgrossman@labcentral.org